RESEARCH APPROACH
PRaG & radioimmunotherapy
PRaG is a developing research approach within radioimmunotherapy. Its central question is how local radiation and systemic immune treatment can work together to control cancer. From the original combination, the research has expanded to explore new agents, schedules and clinical settings.
Local treatment
Radiotherapy targets selected tumor sites. Research also examines how radiation changes the tumor microenvironment and makes tumor antigens available to immune cells.
Systemic immune response
Immune-modulating treatments are combined with radiotherapy to explore responses within and beyond the irradiated sites.
Combination and sequencing
Studies examine which agents to combine, which sites to irradiate and how to sequence treatment, while assessing both tumor control and safety.
From the original regimen to a research program
The Second Affiliated Hospital of Soochow University is central to the development of PRaG. Liyuan Zhang’s university profile dates the work to 2019. The 2022 phase II publication evaluated PD-1 inhibition, radiotherapy and GM-CSF in 54 patients with previously treated metastatic solid tumors. This combination established the starting point for subsequent research.
University profile ↗ · Read the phase II report →
View full size ↗Read from left to right: repeated radiotherapy and immune-treatment cycles were followed by maintenance treatment and imaging assessments. This is the schedule of the 2022 study, rather than a universal schedule for every PRaG-derived approach.
© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 1 · CC BY 4.0. Reproduced without alteration.
A shared question, evolving combinations
Later publications and trial registrations explore additional cytokines, antibody–drug conjugates, other immune-modulating agents and different delivery strategies. The wider purpose is to investigate the interaction between radiotherapy and systemic treatment: which combinations, sequences and clinical settings may improve tumor control with acceptable toxicity.
Each study defines its own regimen and patient population. Our library distinguishes the original PRaG studies, derived approaches and related radioimmunotherapy research, so that the evidence can be read in context. Explore the clinical research program →
Reading the clinical evidence
Published tumor responses support further investigation. The strength of a conclusion depends on the study design, comparison group, follow-up and safety findings. Case reports, single-arm cohorts and comparative studies answer different questions; their results should be read together with their limitations.
Reading the first phase II study → · From cases to clinical evidence →
Frequently asked questions
Is PRaG the same as proton therapy?
No. PRaG refers to a research approach combining radiotherapy with immune treatment. The Chinese name does not imply that proton beams are required.
Do higher version numbers mean better treatment?
The numbered regimens address different combinations and clinical questions. Comparative evidence is needed to establish which approach works better in a particular setting.
Does a complete response mean a cure?
A complete response describes findings at a specified assessment under defined criteria. It does not by itself establish cure or remove the need for follow-up.
How does research inform individual care?
Research describes selected populations. Diagnosis, previous treatment, overall health and available options need an individual assessment by the treating team.